Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study

European Journal of Echocardiography

Volumn 8, Issue 4, 2007, Pages 275-283

  Dart, Anthony M ^a   Otterstad, Jan Erik ^b   Kirwan, Bridget Anne ^c   Parker, John D ^d   de Brouwer, Sophie ^c   Poole Wilson, Philip A ^e   Lubsen, Jacobus ^c,f  

^a ALFRED HOSPITAL   (Australia)

^b VESTFOLD HOSPITAL TRUST   (Norway)

^c SOCAR RESEARCH SA   (Switzerland)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angina; Coronary artery disease; Echocardiography; Left ventricular function; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE; ORGANIC NITRATE; PLACEBO;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORE LABORATORY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; FEMALE; HAZARD RATIO; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PATIENT PARTICIPATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; STANDARDIZATION; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANGINA PECTORIS; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FEMALE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE; PROGNOSIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 34250765740     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1016/j.euje.2007.02.005     Document Type: Article

References (27)

1. Norris R.M., White H.D., Cross D.B., Wild C.J., and Whitlock R.M. Prognosis after recovery from myocardial infarction: the relative importance of cardiac dilatation and coronary stenoses. Eur Heart J 13 (1992) 1611-1618
2. Obeidat O., Alam M., Divine G.W., Khaja F., Goldstein S., and Sabbah H. Echocardiographic predictors of prognosis after first acute myocardial infarction. Am J Cardiol 94 (2004) 1278-1280
3. Lubsen J., Poole-Wilson P.A., Pocock S.J., van Dalen F.J., Baumann J., Kirwan B.A., et al. Design and current status of ACTION: a coronary disease trial investigating outcome with nifedipine GITS, gastro-intestinal therapeutic system. Eur Heart J 19 Suppl. I (1998) I20-I32
4. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J., Wagener G., Danchin N., et al. Effect of long-acting Nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 (2004) 849-857
5. Poole-Wilson P.A., Kirwan B.A., Voko Z., de Brouwer S., van Dalen F.J., and Lubsen J. Safety of Nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther 20 1 (2006) 45-54
6. Kaplan N.M. Do calcium antagonists cause myocardial infarction?. Am J Cardiol 77 (1996) 81-82
7. Opie L.H. Risks and benefits of calcium antagonists. Lancet 346 (1995) 961
8. Poole-Wilson P.A. The calcium antagonist controversy; implications beyond drug prescription. Eur Heart J 17 (1996) 1131-1133
9. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation?. Circulation 92 (1995) 1079-1082
10. Otterstad J.E., Froeland G., St John S.M., and Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 18 (1997) 507-513
11. Gottdiener J.S., Bednarz J., Devereux R., Gardin J., Klein A., Manning W.J., et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17 (2004) 1086-1119
12. Grayburn P.A., Appleton C.P., DeMaria A.N., Greenberg B., Lowes B., Oh J., et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 45 (2005) 1064-1071
13. Skali H., Zornoff L.A., Pfeffer M.A., Arnold M.O., Lamas G.A., Moye L.A., et al. Prognostic use of echocardiography 1 year after a myocardial infarction. Am Heart J 150 (2005) 743-749
14. Kober L., Torp-Pedersen C., Carlsen J., Videbaek R., and Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J 15 12 (1994) 1616-1620
15. Hole T., Otterstad J.E., St J.S., Froland G., Holme I., and Skjaerpe T. Differences between echocardiographic measurements of left ventricular dimensions and function by local investigators and a core laboratory in a 2-year follow-up study of patients with an acute myocardial infarction. Eur J Echocardiogr 3 4 (2002) 263-270
16. Cohn J.N., and Rector T.S. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 62 (1988) 25A-30A
17. Solomon S.D., Anavekar N., Skali H., McMurray J.J., Swedberg K., Yusuf S., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005 December 13) 3738-3744
18. Stadius M.L., Davis K., Maynard C., Ritchie J.L., and Kennedy J.W. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. The Western Washington Intracoronary Streptokinase Trial. Circulation 74 (1986) 703-711
19. Velazquez E.J., Francis G.S., Armstrong P.W., Aylward P.E., Diaz R., O'Connor C.M., et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J 25 (2004) 1911-1919
20. Otterstad J.E., St J.S.M., Froeland G.S., Holme I., Skjaerpe T., and Hall C. Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function. Eur Heart J 23 13 (2002) 1011-1020
21. White H.D., Norris R.M., Brown M.A., Brandt P.W., Whitlock R.M., and Wild C.J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987) 44-51
22. de Vries R.J., van Veldhuisen D.J., and Dunselman P.H. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am Heart J 139 (2000) 185-194
23. Mahon N., and McKenna W.J. Calcium channel blockers in cardiac failure. Prog Cardiovasc Dis 41 (1998) 191-206
24. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
25. O'Connor C.M., Carson P.E., Miller A.B., Pressler M.L., Belkin R.N., Neuberg G.W., et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 82 (1998) 881-887
26. Thackray S., Witte K., Clark A.L., and Cleland J.G. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2 (2000) 209-212
27. Cohn J.N., Ziesche S., Smith R., Anand I., Dunkman W.B., Loeb H., et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 96 (1997) 856-863